Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01154426 | ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01725191 | Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2015 | clinicaltrials |
| NCT01931761 | Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02063204 | To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects | completed | Phase 1 | 24 | AstraZenecaINDUSTRY | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02093728 | To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | completed | Phase 1 | 26 | AstraZenecaINDUSTRY | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00947739 | Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 43 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 18, 2015 | clinicaltrials |
| NCT01544322 | Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors(ME-344-001) | completed | Phase 1 | 24 | MEI Pharma, Inc.INDUSTRY | 1 | Jun 18, 2015 | clinicaltrials |
| NCT00099346 | MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) | terminated | Phase 1 | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT01271972 | Study of Nesvacumab (REGN910/ SAR307746) | completed | Phase 1 | 53 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 16, 2015 | clinicaltrials |
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Ludwig Institute for Cancer ResearchOTHER | 1 | Jun 16, 2015 | clinicaltrials |
| NCT00005078 | Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00005839 | Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor | completed | Phase 1 | — | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00550901 | Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 0 | Jun 8, 2015 | clinicaltrials |
| NCT01602289 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00770263 | Erlotinib and Temsirolimus for Solid Tumors | completed | Phase 1 | 46 | Washington University School of MedicineOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00388427 | Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | completed | Phase 1 | 31 | University of PittsburghOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT00423865 | Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2015 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00535119 | Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | completed | Phase 1 | 107 | National Cancer Institute (NCI)NIH | 1 | May 22, 2015 | clinicaltrials |
| NCT01764087 | A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | May 18, 2015 | clinicaltrials |
| NCT00951158 | A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors | terminated | Phase 1 | 4 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00521144 | Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT01343498 | Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | completed | Phase 1 | 33 | SCRI Development Innovations, LLCOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00020488 | Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00030095 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00042861 | UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00045500 | UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00072111 | Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00003993 | Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 24 | National Institute on Aging (NIA)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019344 | Flavopiridol in Treating Patients With Refractory Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019357 | Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019656 | Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00020150 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | terminated | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT01463982 | Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies | completed | Phase 1 | 21 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 23, 2015 | clinicaltrials |
| NCT00278018 | Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00217373 | Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT00682279 | A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT00021216 | Bortezomib in Treating Children With Advanced Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00255658 | Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01603979 | A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00049400 | S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction | completed | Phase 1 | 78 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2015 | clinicaltrials |
| NCT01081808 | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | terminated | Phase 1 | 2 | Roger Williams Medical CenterOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01847118 | A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 31 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 24, 2015 | clinicaltrials |
| NCT01688960 | Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies | completed | Phase 1 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Mar 17, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2015source: clinicaltrials